*In LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin) in subgroup of del19 patients; OS was secondary endpoint, primary endpoint was PFS and was met.
GIOTRIF® (afatinib) is approved in the European Union and other countries for the treatment of patients with distinct types of metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) mutations.
For more information please see the EU Summary of Product Characteristics (SmPC).
See countries where GIOTRIF® is approved.
‘For optimal user experience this site is best viewed in all recent versions of Google Chrome, Firefox, or Safari. We are working to optimise the site for IE’